Evommune terminates oral drug’s development in CSU
Evommune’s oral MRGPRX2 antagonist has failed to show benefit in patients with chronic spontaneous urticaria (CSU). In a Phase IIb…
Evommune’s oral MRGPRX2 antagonist has failed to show benefit in patients with chronic spontaneous urticaria (CSU). In a Phase IIb…
Moderna has touted the potential of its ever-expanding mRNA platform, which includes an in vivo candidate, during its annual Science…
Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR…
Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a…
The US Department of Health and Human Services (HHS) has announced a coordinated department-wide effort to strengthen America’s leadership in…
MSD’s investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), which it acquired during a $10.8bn buyout of…
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared an investigator-led trial investigating puberty blockers in children and young people…
A draft legislation aimed at accelerating drug discovery and clinical trials has been proposed in the US. Democratic Congressman Jake…
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the…